Skip to content
OpenCapital
Get started

Nuvalent, Inc. NUVL Neladalkib — Direct Expenses Related To Program

Similar metrics at other companies

Medpace Holdings, Inc. logo
MEDPDirect Costs — Total direct costs
$198.27M+11.5%
BioMarin Pharmaceuticals logo
BMRNLater-stage clinical programs — R&D
$36.18M+153%
Medpace Holdings, Inc. logo
MEDPDirect Costs — Segment Reporting, Other Segment Item, Amount
$33.67M-0.6%
Eli Lilly logo
LLYEarly-stage — R&D
$1.27B+27.9%
SPT
SPTXGlyph Allo Direct Research And Development Expenses — Research And Development Expense
——
SPT
SPTXGlyph2BLSD Direct Research And Development Expenses — Research And Development Expense
——

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept nuvl:DirectExpensesRelatedToProgram.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s neladalkib — direct expenses related to program.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s neladalkib — direct expenses related to program?
Nuvalent, Inc. (NUVL) reported neladalkib — direct expenses related to program of $26.32M in Q1 2026.
How has Nuvalent, Inc.'s neladalkib — direct expenses related to program changed year-over-year?
Nuvalent, Inc.'s neladalkib — direct expenses related to program decreased by 6.0% year-over-year, from $28.01M to $26.32M.
What is the long-term trend for Nuvalent, Inc.'s neladalkib — direct expenses related to program?
Over 2 years (2023 to 2025), Nuvalent, Inc.'s neladalkib — direct expenses related to program has grown at a 81.8% compound annual growth rate (CAGR), from $31.89M to $105.45M.
What does neladalkib — direct expenses related to program mean?
The total direct costs incurred to research and develop a specific drug candidate.
How do you interpret neladalkib — direct expenses related to program?
An increase typically signals accelerated clinical trial activity, expanded patient enrollment, or progression into more advanced, cost-intensive trial phases. A decrease may indicate the completion of specific study phases, cost-saving initiatives, or a strategic shift in development priorities.
How does neladalkib — direct expenses related to program compare across companies?
Comparable to R&D program-specific spend or clinical trial expenses reported by other clinical-stage biopharmaceutical companies, though absolute values vary significantly based on trial phase and therapeutic area.